Title: Circulating inflammatory proteins and risk of Parkinson's disease and other neurodegenerative disorders: a two-sample Mendelian randomization study

Authors: Zhichun Chen^{1, 2}, Guanglu Li³, Liche Zhou², Lina Zhang⁴, Yong You^{1,5,6,*} and Jun Liu^{2,*}

Author affiliations:

¹Department of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou 570311, China

²Department of Neurology and Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

³Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China

⁴Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

⁵International Center for Aging and Cancer (ICAC), Hainan Medical University

⁶Key Laboratory of Brain Science Research & Transformation in Tropical Environment of Hainan Province

* Correspondence to:

Jun Liu, Department of Neurology and Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. E-mail: <u>jly0520@hotmail.com</u>

Yong You, Department of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570311, China. E-mail: youyong@hainmc.edu.cn

Title: 147 characters Abstract: 227 words Introduction: 397 words Article: 2764 words Reference: 82 Figures: 3 Supplemental Tables: 1 Supplemental Figures: 2

Abstract

Background: Accumulating studies have suggested associations between peripheral inflammation and neurodegenerative disorders, including Parkinson's disease (PD).

Objective: To evaluate the causal associations between 91 plasma inflammatory proteins and 4 neurodegenerative disorders.

Methods: Two-sample Mendelian randomization studies were performed using summary statistics extracted from genome-wide association studies of 91 plasma inflammatory proteins and 4 neurodegenerative disorders.

Results: Genetically proxied tumor necrosis factor receptor superfamily member 9 levels were causally associated with reduced risk of PD (odds ratio [OR] = 0.82, 95% confidence interval [CI] = 0.74-0.92, $p = 4.18 \times 10^{-4}$, Bonferroni-corrected p < 0.05 for 91 proteins). Additionally, we identified potential causal associations between the levels of C-C motif chemokine 20 (OR = 1.14, 95%CI = 1.03-1.25, $p = 1.29 \times 10^{-2}$) and Alzheimer's disease, between levels of leukemia inhibitory factor receptor (OR = 0.91, 95%CI = 0.84-0.98, $p = 1.12 \times 10^{-2}$) and tumor necrosis factor- β (OR = 0.95, 95%CI = 0.93-0.98, $p = 1.01 \times 10^{-3}$) and amyotrophic lateral sclerosis, between levels of adenosine deaminase (OR = 0.81, 95%CI = 0.71-0.94, $p = 5.14 \times 10^{-3}$) and interleukin-18 (OR = 0.81, 95%CI = 0.69-0.96, $p = 1.68 \times 10^{-2}$) and multiple sclerosis.

Conclusions: Our study unveils plausible causal associations between circulating inflammatory factors and risk of 4 neurodegenerative disorders. These findings hold promise for promoting risk assessment and prevention of neurodegenerative disorders, meriting further exploration.

Keywords: Parkinson's disease; Peripheral inflammation; Mendelian randomization; Neurodegenerative disease.

Introduction

Although current medical and health services have dramatically increased the life expectancy of elderly population, the clinical management of neurodegenerative disorders (NDDs) remains a global health challenge ¹⁻⁷. NDDs are characterized by the progressive degeneration of neural cells in central or peripheral nervous system, resulting in the impairment of motor, sensory, cognitive, emotional, and autonomic processes. Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) are the major types of NDDs, which significantly reduce the life expectancy and quality of life ^{6, 7}.

Over the past decade, increasing evidence has shed light on the important role of peripheral inflammation in the pathogenesis of NDDs⁸. In MS, peripheral immune cells have been shown to trigger neuroinflammation and subsequent demyelination during disease flares^{9, 10} and blocking of circulating T cell infiltration into the brain parenchyma with natalizumab has been shown to be an alternative targeted therapy in clinical management ^{11, 12}. In addition, the mobilization and activation of peripheral immune cells have also been demonstrated to be key drivers of neurodegeneration in AD ^{8, 13}, PD ^{8, 14}, and ALS ^{8, 15, 16}, thus, peripheral inflammation is also an invariant and fundamental feature of AD, PD, and ALS ^{8, 17}. However, due to the complex compositions of peripheral immune system ^{8, 17}, it remains unknown which molecular and cellular components of peripheral inflammation are causally involved in the pathogenesis of NDDs.

Mendelian randomization (MR) is a powerful method that uses randomly assigned genetic variants as proxies of exposures and infers the causal associations between exposure and outcome ^{18, 19}. Considering the critical role of peripheral inflammation in the occurrence of NDDs, it is important to examine whether peripheral immune molecules or cells were causally associated with the risk of NDDs using MR analysis. Previous studies have used MR analysis to estimate the causal associations between immune cell traits and neurological diseases, such as AD^{20, 21}, PD^{21, 22}, ALS^{21, 23}, MS^{24, 25}, myasthenia gravis²⁶, and subarachnoid hemorrhage²⁷. However, how the circulating inflammatory proteins causally associate with NDDs remains to be identified. Zhao *et al.* (2023) conducted a genome-wide protein quantitative trait locus (pQTL) study of 91 circulating inflammatory proteins in 14,824 participants and identified 180 pQTLs (59 *cis*, 121 *trans*)²⁸. In this study, we comprehensively examined the causality between the 4 NDDs and 91 plasma inflammatory proteins using a two-sample MR study.

Methods

Ethical approval

This MR study utilized summary statistics from previous published GWAS with ethical approval by corresponding ethics committee, therefore, additional ethical approval for current study is not required.

Study design

The overall study flowchart is illustrated in Fig. 1. MR analyses were performed in accordance with the STROBE-MR checklist ²⁹ and Burgess *et al.*'s guidelines ³⁰. In this study, we treated the plasma levels of each inflammatory protein as the exposure (a total of 91 inflammatory proteins; sample size: n = 14,824) 28 , and the risk of each NDD (PD, AD, ALS, and MS; sample size: n = 115,803 ~ 482,730) as the outcome in the MR analysis ³¹⁻³⁴. According to the standard protocols of MR study ^{18, 19, 29, 30}, each instrumental variable (IV) should satisfy three assumptions as shown below: (i) The IV is significantly associated with the exposure; (ii) The IV is independent of all the other IVs and potential confounding factors; (iii) The IV affects the outcome only through the exposure. During the MR analysis, multiple statistical approaches, such as inverse variance weighted (IVW) method and weighted median method, were performed, however, only IVW was selected to be the major method to examine causal associations due to its high statistical power ^{35, 36}. To guarantee the statistical robustness of MR analysis, we conducted comprehensive downstream analyses to evaluate potential biases, which might undermine the reliability of our findings. Specifically, we applied MR-RAPS (Robust adjusted profile score)³⁷ to assess the statistical robustness of MR analysis with weak genetic IVs as previously described ^{35, 38}. The code of MR-RAPS is available at https://github.com/gingyuanzhao/mr.raps. MR-Egger regression ³⁹ and Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO; https://github.com/rondolab/MR-PRESSO/)⁴⁰ tests were performed to assess potential bias due to pleiotropy. Leave-one-out (LOO) analyses were conducted to evaluate the bias caused by individual predominant IVs ³⁵. The reverse MR analyses, steiger test of directionality, and steiger filtering were performed to exclude the possibility of reverse causation. All statistical analyses were conducted by TwoSampleMR package installed in R software (version 4.3.1; R Foundation for Statistical Computing, Vienna, Austria).

Exposure data

GWAS data of circulating inflammatory proteins were sourced from https://www.phpc.cam.ac.uk/ceu/proteins and the EBI GWAS Catalog (accession numbers GCST90274758 to GCST90274848)²⁸. This dataset comprised the genome-wide protein quantitative trait locus (pQTL) mapping of 91 plasma inflammatory proteins measured using the Olink Target platform in 14,824 participants of 11 cohorts ²⁸.

Outcome data

The GWAS summary statistics of PD (GWAS ID: ieu-b-7) ³², AD (GWAS ID: ieu-b-2) ³³, ALS (GWAS ID: ebi-a-GCST90027163) ³⁴, and MS (GWAS ID: ieu-b-18) ³¹ were all extracted from IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/). The GWAS of PD involved 33,674 PD cases and 449,056 control individuals from International Parkinson's Disease Genomics Consortium (IPDGC) ³². The GWAS of AD was conducted in 21,982 AD cases and 41,944 controls collected from multiple international cohorts ³³. The GWAS of ALS was conducted in 27,205 ALS cases and 110,881 controls ³⁴. The GWAS of MS was performed in 47,429 MS cases and 68,374 controls from International Multiple Sclerosis Genetics Consortium (IMSGC) ³¹. All participants recruited in above original GWAS were of European ancestry. The GWAS summary statistics of above 4 NDDs have been widely utilized in previous MR studies ^{36,41}.

Selection of genetic IVs

To increase the statistical power of MR analysis, our study initially applied a relaxed statistical *p*-value threshold ($p < 1 \ge 10^{-5}$) to screen the IVs as previously used ³⁸. Then, the linkage disequilibrium (LD) clumping was further implemented using 1000 Genomes Project Phase 3 reference panel for the European populations within a 10 MB window to select SNPs that were independently ($r^2 < 0.001$) associated with circulating inflammatory proteins. If a particular requested SNP was not present in the outcome GWAS, then highly correlated proxy SNPs ($r^2 > 0.8$) were searched as IVs. Heterogeneity test was conducted to detect outliers and improve the accuracy and robustness of IVs and Rucker's Q' test for MR-Egger model was performed to evaluate heterogeneity or directional pleiotropy ⁴². Funnel plot was also utilized to assess the heterogeneity of IVs. p < 0.05 in the heterogeneity test indicated the necessity of IV adjustments.

Removing confounders

SNPs associated with potential confounders, such as drinking and smoking behavior, were removed. Specifically, PhenoScanner V2 (http://www.phenoscanner.medschl.cam.ac.uk/) and NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/docs/file-downloads/) were used to exclude the SNPs associated with confounders.

Two-sample MR analyses

An IVW regression method with a fixed-effects model was employed as the primary causal inference. Complementary MR analyses were conducted using the MR Egger, weighted median, simple mode, and weighted mode methods to strengthen the validity of the IVW estimates. MR-RAPS provided a robust inference for MR analysis using many weak IVs ³⁷. All these methods were implemented by the functions 'mr_ivw', 'mr_egger_regression', 'mr_weighted_median', 'mr_raps', and 'mr_weighted_mode' in the TwoSampleMR v0.4.26 R package. Bonferroni approach was utilized to correct for multiple hypothesis

testing. Significance was defined as Bonferroni-corrected p < 0.05 (uncorrected $p < 5 \ge 10^4$ [0.05/91]), whereas uncorrected p < 0.05 that did not meet the Bonferroni-corrected threshold was suggested as potential causal association.

Sensitivity analysis

First, LOO analysis was performed to examine whether the causal association was particularly driven by a single SNP (p < 0.05 was regarded as an outlier). Second, MR-PRESSO global test (<u>https://github.com/rondolab/MR-PRESSO/</u>) was used to detect IVs affected by horizontal pleiotropy (p < 0.05). Third, an MR-Egger regression was conducted to examine the potential bias of directional pleiotropy. The intercept in the Egger regression was interpreted as evidence of pleiotropy when the value differed from zero (p < 0.05).

Results

The Fig. 2 summarized the overall MR causal estimates. Among 91 plasma inflammatory proteins, only the levels of tumor necrosis factor receptor superfamily member 9 (TNFRSF9) were found to be causally associated with reduced risk of PD (OR = 0.82, 95%CI = 0.74-0.92, $p = 4.18 \times 10^{-4}$, Bonferroni-corrected p < 0.05 for 91 proteins). By contrast, other circulating inflammatory proteins failed to reach statistical significance. For AD, we identified a potential causal association between the levels of C-C motif chemokine 20 (CCL20) and risk of AD (OR = 1.14, 95%CI = 1.03-1.25, $p = 1.29 \times 10^{-2}$). For ALS, the levels of leukemia inhibitory factor receptor (LIFR) (OR = 0.91, 95%CI = 0.84-0.98, $p = 1.12 \times 10^{-2}$) and tumor necrosis factor- β (TNF- β) (OR = 0.95, 95%CI = 0.93-0.98, $p = 1.01 \times 10^{-3}$) were revealed to confer risk of ALS. For MS, the levels of adenosine deaminase (OR = 0.81, 95%CI = 0.71-0.94, $p = 5.14 \times 10^{-3}$) and interleukin-18 (IL-18) (OR = 0.81, 95%CI = 0.69-0.96, $p = 1.68 \times 10^{-2}$) were causally associated with reduced risk of MS. The LOO analyses and other downstream statistical analyses, such as heterogeneity analysis, pleiotropy test, MR-RAPS, Steiger directionality test, and MR-PRESSO test, all supported the reliability of above findings (Supplementary Table 1, Supplementary Fig. 1-2). Zhao et al. (2023) identified a potential causal association between circulating CD40 levels and MS (OR = 0.75, 95%CI = 0.70-0.82, $p = 1.20 \times 10^{-12}$)²⁸, however, in this study, we found the causal association (OR = 0.79 95%CI = 0.73–0.85, $p = 2.91 \times 10^{-10}$) between plasma CD40 levels and MS was biased by a SNP (rs1883832, p =1.07 x 10⁻²⁸¹ in outcome GWAS) strongly associated with the risk of MS (Fig. 3A-C). When the SNP (rs1883832) was removed from the MR models, no significantly causal association was detected (Fig. 3D-**F**).

Discussion

Previous evidence has suggested neuroinflammation in central nervous system plays a key role in the pathogenesis of NDDs ⁴³⁻⁴⁵. Although dysregulated peripheral immunity has also been observed in NDDs according to previous studies^{8-10, 15, 16}, whether peripheral immune dysfunction is causally associated with risk of NDDs is largely unknown. In this study, we demonstrate potential causal relationships between several plasma inflammatory proteins and risk of NDDs. Especially, the levels of TNFRSF9 are causally associated with reduced risk of PD by 18%, which even remains statistically significant after Bonferroni correction for multiple hypothesis testing. Our findings support the causality between circulating inflammatory proteins and risk of 4 NDDs, suggesting that peripheral inflammation has a significant clinical influence on 4 NDDs.

The dysregulations of peripheral immunity have been observed in 4 NDDs ^{8-10, 15-17}. For innate immunity, both monocytes and macrophages have been revealed to be involved in the occurrences of NDDs, including PD ⁴⁶⁻⁴⁸, ALS ^{49, 50}, and MS ^{51, 52}. Abnormal activations of monocytes have been observed in PD patients ^{47,} ⁴⁸ and monocytes seem to exhibit age-dependent impairment of α -synuclein oligomer uptake ⁵³. In ALS, the modification of peripheral macrophages could suppress proinflammatory microglial responses and exert neuroprotection ⁵⁰. In MS, remarkable bone marrow myelopoiesis has been shown to increase the invasion of peripheral neutrophils and Ly6C^{high} monocytes into brain parenchyma ⁵². Especially, Cxcl10⁺ monocytes have been shown to induce experimentally autoimmune encephalomyelitis, a model of MS ⁵⁴. As to adaptive immunity, infiltration of peripheral CD8+ T cells into AD cultures could induce abnormal microglial activation, neuroinflammation and neurodegeneration ¹³. Additionally, PD patients exhibit reduced blood CD8+ cytotoxic T cells, which are primarily associated with the severity of the disease. Importantly, peripheral Th17 lymphocytes from PD patients have been demonstrated to induce neuronal cell death in an iPSC-based PD model 55. In ALS, increased blood CD4+EOMES+ T cells are associated with poor prognosis ⁵⁶ and T cells have been shown to infiltrate into the spinal cord of sporadic ALS patients ⁵⁷. In MS, blood memory B cells are demonstrated to activate autoreactive CD4+ T cells to trigger neuroinflammation and demyelination ⁵⁸. All these findings suggest that peripheral immune dysregulation is a remarkable pathological marker of NDDs. With MR analysis, previous studies have also shown several blood immune cell traits are causally correlated with 4 NDDs, including AD^{20, 21}, PD^{21, 22, 59}, ALS^{21, 23}, and MS^{24, 25}. In this study, we provided new evidence that peripheral inflammatory proteins are also causally associated with NDDs, which further support the causal role of peripheral immune dysregulation in the pathogenesis of NDDs. TNFRSF9 is a receptor for TNFSF9/4-1BBL (also known as CD137L), which is a type II membrane protein of the TNF superfamily. TNFRSF9 could enhance the survival, cytotoxicity, and mitochondrial activity of CD8+ T cell, thereby enhancing immunity against viruses and tumors ^{60, 61}. The levels of TNFRSF9 are increased in PD patients ⁶², especially in those with cognitive impairment ⁶². Patients with mutations in *DJ-1* develop early-onset PD and exhibit slow disease progression, while a novel

variant that contains the partial deletion of neighboring genes DJ-1 (del exons 1-5) and TNFRSF9 (del exons 1-6) is revealed to cause a new type of juvenile PD with remarkably earlier disease onset ⁶³. In current study, we find levels of TNFRSF9 are associated with reduced risk of PD, which indicates TNFRSF9 may play a protective role in PD patients. However, according to previous literature, the specific mechanisms of TNFRSF9 involved in PD pathophysiology have not been investigated before. The dysregulations of T cell immunity have been shown to induce neuroinflammation and dopaminergic neurodegeneration in PD patients ⁶⁴⁻⁶⁷. Considering the key role of TNFRSF9 in the modulation of CD8+ T cells ^{60, 61}, we hypothesize that TNFRSF9 may regulate CD8+ T cells to participate in the neuroinflammation of PD patients. Future studies are required to further decode the molecular and cellular mechanisms underlying the effects of TNFRSF9 in PD patients. We find the levels of CCL-20 are associated with increased risk of AD, which is consistent with previous studies showing that chemokines are associated with cognitive impairment in AD patients ⁶⁸. Although the specific role of CCL-20 in AD has not been studied before, other chemokines, such as CXCL1 and CXCL10, have been shown to mediate neuroinflammation and neurodegeneration in AD models ^{13, 69}. LIFR is a receptor for LIF, which is a member of the IL-6 cytokine family. LIF gene has been shown to be modifier gene in the pathogenesis of ALS ⁷⁰. Interestingly, a recent MR analysis has also revealed that LIFR levels are causally associated with ALS risk ⁷¹, which are consistent with our results. Adenosine deaminase is a key enzyme in purine salvage pathways and the mutations in adenosine deaminase gene cause autosomal recessive severe combined immunodeficiency (SCID). MS patients exhibit elevated levels of adenosine deaminase in CSF ⁷² and elevated adenosine deaminase activities in serum ⁷³. Besides, the distribution of adenosine deaminase isoenzymes has been shown to be impaired in CSF and plasma of MS patients ⁷⁴. It seems that adenosine deaminase may regulate the pathogenesis of MS through adenosinergic signaling ⁷⁵. IL-18 607C/A gene promoter polymorphism has been shown to be a major genetic factor for MS⁷⁶ and the serum levels of IL-18 are increased in MS patients^{77,78}. In this study, we found the plasma IL-18 levels are associated with reduced risk MS patients, indicating IL-18 may play an essential role in the occurrence of MS.

Previous MR analysis reported a causal association between plasma CD40 levels and MS risk ²⁸, however, we didn't completely duplicate their results. In their analysis, they used quasi-independent variants ($r^2 < 0.1$) to select IVs, which may increase LD of IVs and bias of their results. Actually, we found the causal association between plasma CD40 levels and MS may be biased by a risk variant of MS, rs1883832 ³¹. rs1883832 is a *cis*-pQTL of plasma CD40 and the GTEx project has shown that rs1883832 C allele is associated with increased CD40 levels in both blood ($p < 1.6 \times 10^{-13}$) and cerebral cortex ($p < 5.6 \times 10^{-7}$). Additionally, previous studies have shown that the CD40–CD40L costimulatory pathway is implicated in the pathogenesis of MS ⁷⁹⁻⁸¹ and anti-CD40L monoclonal antibody frexalimab has been shown to reduce

the number of new gadolinium-enhancing T1-weighted lesions in MS patients ⁸². Based on these results, we conclude that CD40–CD40L pathway may be causally associated with pathogenesis of MS, however, whether plasma CD40 levels are causally associated with MS risk remains to be further elucidated.

In conclusion, our study indicates the peripheral inflammation may be causally associated with 4 NDDs. Future studies are encouraged to decipher the molecular mechanisms underlying the associations between circulating inflammatory proteins identified in this study and the pathogenesis of 4 NDDs.

Funding

This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415, and 82060213) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).

Author contributions

ZC had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: ZC, YY, and JL. Acquisition, analysis, or interpretation of data: ZC, GL, LZ, and LZ. Drafting of the manuscript: ZC and JL. Critical revision of the manuscript for important intellectual content: ZC, LZ, YY, and JL. Statistical analysis: ZC and GL. Obtained funding: YY and JL.

Competing interests

The authors declare no conflicts of interest.

Availability of data and materials

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Supplementary information

Supplementary data related to this article can be found online.

References

1. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature 2018;561:45-56.

2. Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol 2024;23:277-301.

 Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet 2022;400:1363-1380.

4. Foltynie T, Bruno V, Fox S, Kuhn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet 2024;403:305-324.

5. Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:88-106.

6. Collaborators GBDN. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:459-480.

7. Collaborators GBDNSD. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024;23:344-381.

8. Berriat F, Lobsiger CS, Boillee S. The contribution of the peripheral immune system to neurodegeneration. Nat Neurosci 2023;26:942-954.

9. Sumida T, Lincoln MR, Ukeje CM, et al. Activated beta-catenin in Foxp3(+) regulatory T cells links inflammatory environments to autoimmunity. Nat Immunol 2018;19:1391-1402.

10. Grigg JB, Shanmugavadivu A, Regen T, et al. Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. Nature 2021;600:707-712.

11. Foley JF, Defer G, Ryerson LZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022;21:608-619.

12. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-260.

13. Jorfi M, Park J, Hall CK, et al. Infiltrating CD8(+) T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model. Nat Neurosci 2023;26:1489-1504.

14. Wang P, Yao L, Luo M, et al. Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease. Cell Discov 2021;7:52.

15. Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol 2017;74:1446-1454.

16. Campisi L, Chizari S, Ho JSY, et al. Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4. Nature 2022;606:945-952.

17. Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci 2017;20:136-144.

18. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA 2017;318:1925-1926.

19. Birney E. Mendelian Randomization. Cold Spring Harb Perspect Med 2022;12.

20. Liao J, Zhang Y, Tang Z, Liu P, He L. Causal relationships between peripheral immune cells and Alzheimer's disease: a two-sample Mendelian randomization study. Neurol Sci 2024.

21. Tang C, Lei X, Ding Y, Yang S, Ma Y, He D. Causal relationship between immune cells and neurodegenerative diseases: a two-sample Mendelian randomisation study. Front Immunol 2024;15:1339649.

22. Gu J, Qiao Y, Cong S. Causal role of immune cells on risk of Parkinson's disease: a Mendelian randomization study. Front Aging Neurosci 2024;16:1368374.

23. Gong Z, Liu Y, Ding F, Ba L, Zhang M. Natural killer cells-related immune traits and amyotrophic lateral sclerosis: A Mendelian randomization study. Front Neurosci 2022;16:981371.

24. He D, Liu L, Shen D, Zou P, Cui L. The Effect of Peripheral Immune Cell Counts on the Risk of Multiple Sclerosis: A Mendelian Randomization Study. Front Immunol 2022;13:867693.

25. Chen L, Zhu LF, Zhang LY, et al. Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis. Front Immunol 2024;15:1325938.

26. Zhong H, Jiao K, Huan X, et al. Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study. Front Immunol 2022;13:931821.

27. Yan C, Li Y. Causal Relationships Between Gut Microbiota, Inflammatory Cells/Proteins, and Subarachnoid Hemorrhage: A Multi-omics Bidirectional Mendelian Randomization Study and Metaanalysis. Mol Neurobiol 2024.

28. Zhao JH, Stacey D, Eriksson N, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 2023;24:1540-1551.

29. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 2021;326:1614-1621.

30. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res 2019;4:186.

31. International Multiple Sclerosis Genetics C. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019;365.

32. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091-1102.

33. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 2019;51:414-430.

34. van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 2021;53:1636-1648.

35. Guo J, Yu K, Dong SS, et al. Mendelian randomization analyses support causal relationships between brain imaging-derived phenotypes and risk of psychiatric disorders. Nat Neurosci 2022;25:1519-1527.

36. Zeng R, Wang J, Zheng C, et al. Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders. Mov Disord 2023;38:1082-1088.

37. Zhao QY, Wang JS, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summarydata Mendelian randomization using robust adjusted profile score. Ann Stat 2020;48:1742–1769.

38. Zanoaga MD, Friligkou E, He J, et al. Brainwide Mendelian Randomization Study of Anxiety Disorders and Symptoms. Biol Psychiatry 2024;95:810-817.

39. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-525.

40. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018;50:693-698.

41. Li D, Zhou L, Cao Z, et al. Associations of environmental factors with neurodegeneration: An exposome-wide Mendelian randomization investigation. Ageing Res Rev 2024;95:102254.

42. Rucker G, Schwarzer G, Carpenter JR, Binder H, Schumacher M. Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. Biostatistics 2011;12:122-142.

43. Peruzzotti-Jametti L, Willis CM, Krzak G, et al. Mitochondrial complex I activity in microglia sustains neuroinflammation. Nature 2024;628:195-203.

44. Bartels T, De Schepper S, Hong S. Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science 2020;370:66-69.

45. Sun N, Victor MB, Park YP, et al. Human microglial state dynamics in Alzheimer's disease progression. Cell 2023;186:4386-4403 e4329.

46. Navarro E, Udine E, de Paiva Lopes K, et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nat Aging 2021;1:850-863.

47. Grozdanov V, Bliederhaeuser C, Ruf WP, et al. Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol 2014;128:651-663.

48. Grozdanov V, Bousset L, Hoffmeister M, et al. Increased Immune Activation by Pathologic alpha-Synuclein in Parkinson's Disease. Ann Neurol 2019;86:593-606.

49. McCauley ME, O'Rourke JG, Yanez A, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature 2020;585:96-101.

50. Chiot A, Zaidi S, Iltis C, et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci 2020;23:1339-1351.

51. Ortega MC, Lebron-Galan R, Machin-Diaz I, et al. Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis. Acta Neuropathol 2023;146:263-282.

52. Shi K, Li H, Chang T, et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell 2022;185:2234-2247 e2217.

53. Bliederhaeuser C, Grozdanov V, Speidel A, et al. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol 2016;131:379-391.

54. Giladi A, Wagner LK, Li H, et al. Cxcl10(+) monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. Nat Immunol 2020;21:525-534.

55. Sommer A, Marxreiter F, Krach F, et al. Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson's Disease. Cell Stem Cell 2018;23:123-131 e126.

56. Chen S, Huan X, Xu CZ, et al. Eomesodermin expression in CD4(+)T-cells associated with disease progression in amyotrophic lateral sclerosis. CNS Neurosci Ther 2024;30:e14503.

57. Garofalo S, Cocozza G, Bernardini G, et al. Blocking immune cell infiltration of the central nervous system to tame Neuroinflammation in Amyotrophic lateral sclerosis. Brain Behav Immun 2022;105:1-14.

58. Jelcic I, Al Nimer F, Wang J, et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4(+)T Cells in Multiple Sclerosis. Cell 2018;175:85-100 e123.

59. Tian J, Zuo C, Shi J, Ma D, Shi C. Peripheral immune cell traits and Parkinson's disease: A Mendelian randomization study. PLoS One 2024;19:e0299026.

60. Pichler AC, Carrie N, Cuisinier M, et al. TCR-independent CD137 (4-1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation. Immunity 2023;56:1631-1648 e1610.

Otano I, Azpilikueta A, Glez-Vaz J, et al. CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat Commun 2021;12:7296.
 Hepp DH, van Wageningen TA, Kuiper KL, et al. Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson's Disease. Int J Mol Sci 2023;24.

63. Guler S, Gul T, Guler S, Haerle MC, Basak AN. Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes. Mov Disord 2021;36:2973-2976.

64. Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease. Brain 2021;144:2047-2059.

65. Subbarayan MS, Hudson C, Moss LD, Nash KR, Bickford PC. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an alpha-synuclein rat model of Parkinson's disease. J Neuroinflammation 2020;17:242.

66. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009;119:182-192.

67. Galiano-Landeira J, Torra A, Vila M, Bove J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease. Brain 2020;143:3717-3733.

68. Zhou F, Sun Y, Xie X, Zhao Y. Blood and CSF chemokines in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis. Alzheimers Res Ther 2023;15:107.

69. Perez-Nievas BG, Johnson L, Beltran-Lobo P, et al. Astrocytic C-X-C motif chemokine ligand-1 mediates beta-amyloid-induced synaptotoxicity. J Neuroinflammation 2021;18:306.

70. Giess R, Beck M, Goetz R, Nitsch RM, Toyka KV, Sendtner M. Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis. Neurology 2000;54:1003-1005.

71. Xiao C, Gu X, Feng Y, Shen J. Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis. Front Aging Neurosci 2024;16:1367106.

72. Samuraki M, Sakai K, Odake Y, et al. Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid. Mult Scler Relat Disord 2017;13:44-46.

73. Polachini CR, Spanevello RM, Casali EA, et al. Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis. Neuroscience 2014;266:266-274.

74. Kutryb-Zajac B, Kawecka A, Caratis F, et al. The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid. Front Mol Neurosci 2022;15:998023.

75. Duarte-Silva E, Ulrich H, Oliveira-Giacomelli A, Hartung HP, Meuth SG, Peixoto CA. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Front Immunol 2022;13:946698.

76. Orhan G, Eruyar E, Mungan SO, Ak F, Karahalil B. The association of IL-18 gene promoter polymorphisms and the levels of serum IL-18 on the risk of multiple sclerosis. Clin Neurol Neurosurg 2016;146:96-101.

77. Chen YC, Chen SD, Miao L, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol 2012;243:56-60.

78. Jahanbani-Ardakani H, Alsahebfosoul F, Etemadifar M, Abtahi SH. Interleukin 18 Polymorphisms and its serum level in Patients with Multiple Sclerosis. Ann Indian Acad Neurol 2019;22:474-476.

79. Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci 1996;93:2499-2504.

80. Aarts S, Seijkens TTP, van Dorst KJF, Dijkstra CD, Kooij G, Lutgens E. The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front Immunol 2017;8:1791.

81. Aarts SA, Seijkens TT, Kusters PJ, et al. Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis. J Pathol 2019;247:471-480.

82. Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med 2024;390:589-600.

Figure legends

Fig. 1 Workflow of the causal inference between circulating inflammatory proteins and NDDs. Abbreviations: NDD, Neurodegenerative disorder; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; GWAS, Genome-wide association study; SNP, single nucleotide polymorphism; IV, Instrumental variable; LD, Linkage disequilibrium; MAF, minor allele frequency; MR, Mendelian randomization; IVW, Inverse variance weighted; MR-RAPS, Mendelian randomization-robust adjusted profile score; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier.

Fig. 2 Causalities in the MR analysis. **A-F** The forest plot shows the significant causalities in PD (**A**), AD (**B**), ALS (**C-D**), and MS (**E-F**). The effect estimates represent the OR of disorder and error bars represent 95% CIs. All statistical tests were two sided. $p < 5 \times 10^{-4}$ after Bonferroni correction was considered significant. Causal effects were estimated using five two-sample MR methods (MR-Egger, IVW, weighted median, weighted mode, and simple mode). Abbreviations: AD, Alzheimer's disease; PD, Parkinson's disease; ALS, Amyotrophic lateral sclerosis; MS, Multiple sclerosis; TNFRSF9, Tumor necrosis factor receptor; TNF-β, Tumor necrosis factor-β; IL-18, Interleukin-18; MR, Mendelian randomization; IVW, Inverse variance weighted; MR-RAPS, Mendelian randomization-robust adjusted profile score; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier.

Fig. 3 The MR causal estimates between plasma CD40 level and risk of MS. **A-C** The causal association between plasma CD40 levels and MS is determined by rs1883832, which is strongly associated with the risk of MS ($p = 1.07 \times 10^{-281}$). **D-F** When the rs1883832 was removed from the MR models, no significantly causal association was detected. Abbreviations: SNP, single nucleotide polymorphism; MR, Mendelian randomization; MS, Multiple sclerosis.



Harmonization process

- The uniformity of effect allele and effect direction
- Variants with MAF > 0.001
- Removing the palindromic SNPs
- Removing the long-range LD in the genome

MR analysis

- Forward MR analysis: IVW, MR-Egger, Weighted median...
- Reverse MR analysis: IVW, MR-Egger, Weighted median...

Quality control

- Remove heterogeneous IVs revealed by heterogeneity analysis (p < 0.05)
- Assess the statistical robustness of weak IVs using MR-RAPS

Causal directionality analysis

- Steiger test of directionality using directionality_test()
- Steiger filtering using steiger_filtering()

Sensitivity analysis

- Horizontal pleiotropy analysis using mr_pleiotropy_test()
- Leave-one-out analysis using mr_leaveoneout()
- MR-PRESSO global test using mr_presso()



Effect estimate (OR) and 95% CIs

Effect estimate (OR) and 95% CIs

```
MR-RAPS: p = 1.19 x 10<sup>-2</sup>
           MR-PRESSO: p >0.05
p = 9.13 \times 10^{-1}, OR = 1.01 (0.80 to 1.29)
p = 8.21 \times 10^{-1}, OR = 0.97 (0.73 to 1.29)
p = 4.30 \times 10^{-1}, OR = 1.06 (0.92 to 1.22)
p = 1.29 \times 10^{-2}, OR = 1.14 (1.03 to 1.25)
p = 3.71 \times 10^{-1}, OR = 1.14 (0.86 to 1.53)
```

MR-RAPS: $p = 1.07 \times 10^{-3}$ MR-PRESSO: p >0.05 $p = 4.60 \times 10^{-2}$, OR = 0.97 (0.94 to 1.00) $p = 7.56 \times 10^{-1}$, OR = 0.98 (0.85 to 1.12) $p = 2.87 \times 10^{-2}$, OR = 0.97 (0.94 to 1.00) $p = 1.01 \times 10^{-3}$, OR = 0.95 (0.93 to 0.98) $p = 7.74 \times 10^{-1}$, OR = 0.97 (0.94 to 1.00)

```
MR-RAPS: p = 1.96 \times 10^{-2}
        MR-PRESSO: p >0.05
p = 7.09 \times 10^{-2}, OR = 0.69 (0.48 to 0.99)
p = 4.85 \times 10^{-2}, OR = 0.66 (0.46 to 0.95)
p = 1.26 \times 10^{-2}, OR = 0.74 (0.58 to 0.94)
p = 1.68 \times 10^{-2}, OR = 0.81 (0.69 to 0.96)
p = 5.85 \times 10^{-1}, OR = 1.17 (0.67 to 2.04)
```



Β

'CD40 level' on 'MS risk'



Α



Ε







